Nakagawa Masatsugu, Katakura Hiromichi, Adachi Masashi, Takenaka Kazumasa, Yanagihara Kazuhiro, Otake Yosuke, Wada Hiromi, Tanaka Fumihiro
Department of Thoracic Surgery, Kyoto University, 54 Shogoin Kawara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Ann Surg Oncol. 2006 Nov;13(11):1517-23. doi: 10.1245/s10434-006-9030-z.
Maspin is a member of the serpin (serine protease inhibitor) superfamily, and its exact function in the development and progression of malignant tumors remains controversial, though some experimental studies have revealed potential tumor-suppressor activities. In addition, there have been only a few clinical studies on maspin expression in malignant tumors including non-small cell lung cancer (NSCLC). The purpose of this study was to assess maspin expression and its clinical significance in NSCLC.
A total of 210 consecutive patients with completely resected pathological (p-) stage I-IIIA NSCLC were retrospectively reviewed. Maspin expression along with intratumoral microvessel density, proliferative activity, and p53 status were evaluated immunohistochemically. The incidence of apoptotic cell death was also evaluated.
The incidence of strong maspin expression was significantly higher in lung squamous cell carcinoma (56/76, 73.7%; P < .001) than in other histological types. The incidence of aberrant expression of p53 was significantly higher in maspin-strong than in maspin-weak tumors (56.2% and 35.8%, respectively; P = .005). There was no difference in prognosis according to maspin status for all patients. However, for squamous cell carcinoma patients, univariate analysis showed that enhanced maspin expression was a significant factor in predicting a favorable prognosis (5-year survival rates, 70.1% for maspin-strong tumors and 41.5% for maspin-weak tumors; P = .014), which was confirmed in a multivariate analysis (hazard ratio = .475, 95% confidence interval .241-.936; P = .032).
Enhanced maspin expression was a significant and independent factor in predicting a favorable prognosis in lung squamous cell carcinoma.
Maspin是丝氨酸蛋白酶抑制剂（serpin）超家族的成员，尽管一些实验研究已揭示其潜在的肿瘤抑制活性，但其在恶性肿瘤发生发展中的确切功能仍存在争议。此外，关于包括非小细胞肺癌（NSCLC）在内的恶性肿瘤中maspin表达的临床研究较少。本研究旨在评估NSCLC中maspin的表达及其临床意义。
回顾性分析210例连续接受完全切除的病理（p-）I-IIIA期NSCLC患者。采用免疫组织化学方法评估maspin表达以及肿瘤内微血管密度、增殖活性和p53状态。同时评估凋亡细胞死亡的发生率。
肺鳞状细胞癌中maspin强表达的发生率显著高于其他组织学类型（56/76，73.7%；P <.001）。p53异常表达的发生率在maspin强表达肿瘤中显著高于maspin弱表达肿瘤（分别为56.2%和35.8%；P =.005）。所有患者的预后根据maspin状态无差异。然而，对于鳞状细胞癌患者，单因素分析显示maspin表达增强是预测良好预后的重要因素（5年生存率，maspin强表达肿瘤为70.1%，maspin弱表达肿瘤为41.5%；P =.014），多因素分析证实了这一点（风险比 =.475，95%置信区间.241-.936；P =.032）。
maspin表达增强是预测肺鳞状细胞癌良好预后的重要独立因素。
Zotero 插件